Anti-TNF immunogenicity in a Middle Eastern inflammatory bowel disease cohort: prevalence, predictors and context-specific drug level thresholds - Top-Institutions - MDSpire

Anti-TNF immunogenicity in a Middle Eastern inflammatory bowel disease cohort: prevalence, predictors and context-specific drug level thresholds

  • By

  • Shaima Wasim Khan

  • Noorah Al Hosani

  • Thaer Khaleel Swaid

  • Mazin M Edan

  • Mohammed Nabil Quraishi

  • June 26, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    SSMC IBD registry
    SSMC IBD registry

    Abu Dhabi, Abu Dhabi

    Key Differentiators

    • Gastroenterology

  • #2

    tertiary care IBD facility in Abu Dhabi
    tertiary care IBD facility in Abu Dhabi

    Abu Dhabi, Abu Dhabi

    Key Differentiators

    • Gastroenterology

  • #3

    University of California San Diego
    University of California San Diego

    La Jolla, California

    Key Differentiators

    • Gastroenterology

  • #4

    NYU Langone Health
    NYU Langone Health

    New York, New York

    Key Differentiators

    • Gastroenterology

Original Source(s)

Anti-TNF immunogenicity in a Middle Eastern inflammatory bowel disease cohort: prevalence, predictors and context-specific drug level thresholds

  • by Shaima Wasim Khan, Noorah Al Hosani, Thaer Khaleel Swaid, Mazin M Edan, Mohammed Nabil Quraishi

  • June 26, 2026

Related Content

Risk of intestinal involvement in mucocutaneous-onset Behçet’s disease: data from the AIDA network registry

Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn’s disease

Nurr1 deficiency orchestrates a coupled liver–gut pathological axis revealed by multi-omics and deep-learning histopathology